Hidrasec (Racecadotril)

Hidrasec is indicated for the symptomatic relief of acute watery diarrhea in both adults and children. It is used as part of a rehydration strategy to manage fluid loss.

• Acute watery diarrhea in adults
• Acute watery diarrhea in children
• Adjunct to oral rehydration therapy
• Short‑term management of diarrheal episodes
• Support of electrolyte absorption during diarrheal illness

• Racecadotril acts as a peripheral enkephalinase inhibitor, preventing the breakdown of endogenous enkephalins in the intestinal mucosa. Elevated enkephalin levels reduce hypersecretion of water and electrolytes by modulating enteric neuronal pathways, thereby enhancing fluid absorption without affecting intestinal motility.

Adverse reactions to Hidrasec are generally mild but can vary in frequency and severity.

Common

• Nausea
• Abdominal discomfort or pain
• Headache
• Dizziness
• Mild skin rash

Serious

• Severe allergic reaction (anaphylaxis)
• Angioedema
• Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before using Hidrasec, consider the following safety points to minimize risks.

• Assess the degree of dehydration and replace fluids appropriately.
• Use with caution in patients with renal impairment.
• Monitor electrolyte status during prolonged diarrheal episodes.
• Pediatric dosing should follow established guidelines; avoid use in infants under two months.
• Pregnancy and lactation safety have not been established; consult a healthcare professional.
• Discontinue if severe rash or allergic symptoms develop.

Potential drug interactions may affect the efficacy or safety of Hidrasec.

Avoid

• Concurrent use with other antidiarrheal agents (e.g., loperamide) that may cause excessive constipation.
• Strong opioid analgesics that could alter enkephalin pathways.

Use with caution

• Antihypertensive medications, as fluid shifts may affect blood pressure.
• Diuretics, due to combined effects on electrolyte balance.
• NSAIDs, which may increase risk of gastrointestinal irritation.